Sie sind hier: Startseite > News > Gilde Healthcare II portfolio company AMT Appoints New Chief Executive Officer

NEWS.

 

Gilde Healthcare II portfolio company AMT Appoints New Chief Executive Officer

Press Release September 24, 2009 - Abstract

Amsterdam, The Netherlands – September 24, 2009 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced today the appointment of Jörn Aldag as its new Chief Executive Officer, starting October 5. Mr. Aldag has a strong record of accomplishments in the life sciences sector and more than twenty five years of experience in corporate management and finance. As former President and CEO of Evotec AG, he was instrumental in transforming the company from a technology provider to one of the leading drug discovery and development companies in Europe.

Prof. Sander van Deventer will step down as interim-CEO of AMT. He will continue to contribute to AMT as Scientific Advisor.

Ferdinand Verdonck, Chairman, voiced the satisfaction of the members of the Supervisory Board that Mr. Aldag - who was their choice amongst a field of strong candidates - is set to take on the responsibilities as AMT’s CEO. They are confident that AMT will greatly benefit from Mr. Aldag’s acumen and proven management skills and that the company’s scientists and staff will maintain their enthusiastic commitment to develop novel therapeutic cures under his focused guidance. The Supervisory Board looks forward to Mr. van Deventer’s continuing excellent contributions as Scientific Advisor to the company.

Source: http://www.gildehealthcare.nl/39/news/2009/372/gilde-healthcare-ii-portfolio-company-amt-appoints-new-chief-executive-officer/

Press Release (complete)

More information about Gilde at www.gildehealthcare.nl
 

Artikelaktionen